Use of chitosan oligosaccharide in preparation of medicines for preventing and treating cardiovascular and cerebrovascular diseases

A technology for cardiovascular and cerebrovascular diseases and cerebrovascular diseases, which is applied in the field of medicine to achieve the effects of high safety, low cost and wide sources

Inactive Publication Date: 2011-10-12
北京联合大学应用文理学院
View PDF2 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the treatment of cer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of chitosan oligosaccharide in preparation of medicines for preventing and treating cardiovascular and cerebrovascular diseases
  • Use of chitosan oligosaccharide in preparation of medicines for preventing and treating cardiovascular and cerebrovascular diseases
  • Use of chitosan oligosaccharide in preparation of medicines for preventing and treating cardiovascular and cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Embodiment 1 chitosan oligosaccharide anti-cerebral ischemia-reperfusion effect

[0016] 1 Materials and methods

[0017] 1.1 Materials

[0018] 1.1.1 Experimental animals

[0019] Male ICR mice, weighing 25-28 g, were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., license number: SCXK (Beijing) 2007-001. Raised in a natural light cycle, fasted for 12 hours before the operation, and had free access to water.

[0020] 1.1.2 Drugs and reagents

[0021] Oligochitosan (purity ≥ 90%, average molecular weight 1500, degree of deacetylation ≥ 90%): School of Biochemical Engineering, Beijing Union University; Edaravone: Nanjing Xiansheng Dongyuan Pharmaceutical Co., Ltd.; red tetrazole (2, 3,5-triphenyltetrazolium chloride, TTC), Beijing Baierdi Biotechnology Co., Ltd.; malondialdehyde (MDA), carbonyl, superoxide dismutase (SOD), catalase (CAT), glutathione- Peroxidase (GSH-Px), Coomassie Brilliant Blue kit, Nanjing Jiancheng Institute of Bio...

Embodiment 2

[0053] Embodiment 2 chitosan oligosaccharide anti-brain hypoxia effect

[0054] 1 Materials and methods

[0055] 1.1 Materials

[0056] 1.1.1 Experimental animals

[0057] Male ICR mice, weighing 25-28 g, were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., license number: SCXK (Beijing) 2007-001. Raised in a natural light cycle, fasted for 12 hours before the operation, and had free access to water.

[0058] 1.1.2 Drugs and reagents

[0059] Oligochitosan (purity ≥ 90%, average molecular weight 1500, degree of deacetylation ≥ 90%): School of Biochemical Engineering, Beijing Union University; sodium nitrite, Xi'an Chemical Reagent Factory.

[0060] 1.1.3 Experimental Instruments

[0061] AR-2140 1 / 10,000 electronic balance: Mettler-Toledo Instrument Co., Ltd.

[0062] 1.2 Method

[0063] 1.2.1 Grouping and administration of animals

[0064] The mice were randomly divided into 6 groups, namely, sham operation group, model group, edaravone ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Login to view more

Abstract

The invention belongs to the technical field of medicines and relates to the use of the chitosan oligosaccharide in the preparation of medicines for preventing and treating cardiovascular and cerebrovascular diseases. Pharmacodynamic experiments prove that chitosan has remarkable effect of resisting cerebral ischemia, cerebral anoxia and the like, is widely available, can be absorbed easily by bodies, has small toxic and side effects and has a bright application prospect.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to the application of chitosan oligosaccharides in the preparation of medicines for preventing and treating cardiovascular and cerebrovascular diseases, in particular to the application of chitosan oligosaccharides in the preparation of medicines for preventing and treating cerebrovascular diseases. Background technique [0002] In recent years, with the improvement of living standards and changes in dietary patterns, the morbidity and mortality of cardiovascular and cerebrovascular diseases, which are the "number one killer" of human beings, are on the rise. Tens of millions of patients die of cardiovascular and cerebrovascular diseases every year. Although about half of the patients survived after being rescued, they are left with disabilities, cannot take care of themselves, and are under physical and psychological pressure. Epidemiological data speculate that by 2020, cardiovascu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/722A61P9/00A61P9/10
Inventor 姜招峰孙雅煊刘婷戴雪伶高兆兰张静王振华郑秋生
Owner 北京联合大学应用文理学院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap